ArticleJournal of cancer research and clinical oncology2023
A novel staging system based on deep learning for overall survival in patients with esophageal squamous cell carcinoma.
Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Machine learning applications in the detection and treatment of esophageal cancer.Discover oncology · 2026Review
- AI in esophageal cancer: advances, barriers to clinical translation, and perspectives for digital health.Journal of translational medicine · 2026Review
- Advanced biomaterials and digital twins for precision psychiatry: neuroimmune modulation and AI-guided therapeutics.Frontiers in bioengineering and biotechnology · 2026Article
- Functional personalization in digital manufacturing: a translational framework for patient-specific implants, arthroscopic locators, and therapeutic constructs.Frontiers in bioengineering and biotechnology · 2026Article
- Machine learning survival prediction in esophageal cancer using radiomics and body composition from pretreatment and follow-up T12-level computed tomography.World journal of gastrointestinal oncology · 2025Article
- Current Role of Artificial Intelligence in the Management of Esophageal Cancer.Journal of clinical medicine · 2025Review
- Tumor-lymph cross-plane projection reveals spatial relationship features: a ResNet-CBAM model for prognostic prediction in esophageal cancer.Frontiers in oncology · 2025Article
- Artificial intelligence enhances the management of esophageal squamous cell carcinoma in the precision oncology era.World journal of gastroenterology · 2024Review
- Artificial intelligence: clinical applications and future advancement in gastrointestinal cancers.Frontiers in artificial intelligence · 2024Review
- Development and validation of esophageal cancer prediction model based on DeepSurv model: A cohort study.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe developed DeepSurv, a deep learning approach for predicting overall survival (OS) in patients with esophageal squamous cell carcinoma (ESCC). We validated and visualized the novel staging system based on DeepSurv using data from multiple cohorts.
methodsTotally 6020 ESCC patients diagnosed from January 2010 to December 2018 were included in the present study from the Surveillance, Epidemiology, and End Results database (SEER), randomly assigned to the training and test cohorts. We developed, validated and visualized a deep learning model that included 16 prognostic factors; then a novel staging system was further constructed based on the total risk score derived from the deep learning model. The classification performance at 3-year and 5-year OS was assessed by the receiver-operating characteristic (ROC) curve. Calibration curve and the Harrell's concordance index (C-index) were also used to comprehensively assess the predictive performance of the deep learning model. Decision curve analysis (DCA) was utilized to assess the clinical utility of the novel staging system.
resultsA more applicable and accurate deep learning model was established, which outperformed the traditional nomogram in predicting OS in the test cohort (C-index: 0.732 [95% CI 0.714-0.750] versus 0.671 [95% CI 0.647-0.695]). The ROC curves at 3-year and 5-year OS for the model also showed good discrimination ability in the test cohort (Area Under the Curve [AUC] at 3-/5-year OS = 0.805/0.825). Moreover, using our novel staging system, we observed a clear survival difference among different risk groups (P < 0.001) and a significant positive net benefit in the DCA.
conclusionsA novel deep learning-based staging system was constructed for patients with ESCC, which performed a significant discriminability for survival probability. Moreover, an easy-to-use web-based tool based on the deep learning model was also implemented, offering convenience for personalized survival prediction. We developed a deep learning-based system that stages patients with ESCC according to their survival probability. We also created a web-based tool that uses this system to predict individual survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.